Use of an algorithm applied to urine drug screening to assess adherence to an OxyContin® regimen

Journal of Opioid Management

Volumn 5, Issue 6, 2009, Pages 359-364

  Couto, Joseph E ^a   Webster, Lynn ^b   Romney, Martha C ^a   Leider, Harry L ^c   Linden, Ariel ^d  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b Lifetree Clinical Research and Lifetree Pain Clinical   (United States)

^c Ameritox Ltd   (United States)

^d LINDEN CONSULTING GROUP   (United States)

Author keywords

Algorithm; Medication adherence; Oxycodone; Oxycontin ; Urine drug testing

Indexed keywords

OXYCODONE; NALTREXONE; NARCOTIC ANALGESIC AGENT; NARCOTIC ANTAGONIST;

ADULT; ALGORITHM; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG HALF LIFE; DRUG SCREENING; DRUG URINE LEVEL; FEMALE; HUMAN; HUMAN EXPERIMENT; LIQUID CHROMATOGRAPHY; MALE; MASS SPECTROMETRY; NORMAL HUMAN; PATIENT COMPLIANCE; RANDOMIZED CONTROLLED TRIAL; STEADY STATE; URINALYSIS; ADOLESCENT; METHODOLOGY; MIDDLE AGED; OPIATE ADDICTION; PREDICTION AND FORECASTING; REPRODUCIBILITY; SUBSTANCE ABUSE; TANDEM MASS SPECTROMETRY; URINE;

ADOLESCENT; ADULT; ALGORITHMS; ANALGESICS, OPIOID; CHROMATOGRAPHY, LIQUID; FEMALE; HUMANS; MALE; MEDICATION ADHERENCE; MIDDLE AGED; NALTREXONE; NARCOTIC ANTAGONISTS; OPIOID-RELATED DISORDERS; OXYCODONE; PREDICTIVE VALUE OF TESTS; REPRODUCIBILITY OF RESULTS; SUBSTANCE ABUSE DETECTION; TANDEM MASS SPECTROMETRY; URINALYSIS; YOUNG ADULT;

EID: 75649132298     PISSN: 15517489     EISSN: None     Source Type: Journal    
DOI: 10.5055/jom.2009.0035     Document Type: Article

References (17)

1. Substance Abuse and Mental Health Services Administration: National estimates from the drug abuse warning network [homepage on the Internet]. Washington, DC: Substance Abuse and Mental Health Services Administration. Available at http://www.fda.gov/ohrms/dockets/AC/08/slides/2008-4395s1-07- Poneleit.ppt. Accessed July 13, 2009.
2. Office of Applied Studies: Results from the 2007 National Survey on Drug Use and Health: National Findings. Rockville, MD: Substance Abuse and Mental Health Administration, 2008.
3. Kell MJ: Utilization of plasma and urine methadone concentrations to optimize treatment in maintenance clinics. I. Measurement for a clinical setting. J Addict Dis. 1994; 13(1): 5-26.
4. Kell MJ: Utilization of plasma and urine methadone concentration measurements to limit narcotics use in methadone maintenance patients. II. Generation of plasma concentration response curves. J Addict Dis. 1995; 14(1): 85-108.
5. Purdue Pharma L.P.: OxyContin [package insert]. Stamford, CT: Purdue Pharma L.P., 2009.
6. Lin LI: A concordance correlation coefficient to evaluate reproducibility. Biometrics. 1989; 45: 255-268.
7. Lin LIK: A note on the concordance correlation coefficient. Biometrics. 2000; 56: 324-325.
8. Bonett DG, Price RM: Statistical inference for a linear function of medians: Confidence intervals, hypothesis testing, and sam-ple size requirements. Psychological Methods. 2002; 7: 370-383.
9. Price RM, Bonett DG: Estimating the variance of the sample median. J Stat Comput Simul. 2001; 68: 295-305.
10. Price RM, Bonett DG: Distribution-free confidence intervals for difference and ratio of medians. J Stat Comput Simul. 2002; 72: 119-124.
11. Steichen TJ, Cox NJ: Concordance correlation coefficient. Stata Tech Bull. 1998; 43: 35-39.
12. Steichen TJ, Cox NJ: Software update for concord. Stata J. 2008; 8(4): 594.
13. Cox NJ: Speaking stata: Graphing agreement and disagreement. Stata J. 2004; 4(3): 329-349. [homepage on the Internet]. Stata Corporation. Available at http://ideas.repec.org/cgi-bin/htsearch?q= graphing+agreement+and+disagreement&cmd=Search%21&form=extended&m= all&ps=10&fmt=long&wm=wrd&sp=1&sy=1&wf=4BFF&dt= range&db=&de=. Accessed May 1, 2009.
14. Newson R: BPMEDIAN: Stata module to compute Bonett-Price confidence intervals for medians and their contrasts [homepage on the Internet]. Statistical Software Components (SSC). Available at http://ideas.repec.org/ cgi-bin/htsearch?q=bpmedian%3A+&cmd=Search%21. Accessed June 3, 2009.
15. Ingelman-Sundberg M: Genetic polymorphisms of cytochrome P450 2D6 (CYP2D6): Clinical consequences, evolutionary aspects and functional diversity. Pharmacogenomics J. 2005; 5: 6-13.
16. Evans WE, Relling MV, Rahman A, et al.: Genetic basis for a lower prevalence of deficient CYP2D6 oxidative drug metabolism phenotypes in Black Americans. J Clin Invest. 1993; 91: 2150-2154.
17. Bradford LD: CYP2D6 allele frequency in European Caucasians, Asians, Africans and their descendants. Pharmacogenomics. 2002; 3(2): 229-243.